Arm B: Ribociclib + Fulvestrant clinical trials

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

This study looks at new drug combinations for advanced breast cancer. It compares a new treatment (gedatolisib with other drugs) to standard treatments. The aim is to find better ways to treat hormone-positive, HER2-negative breast cancer that has spread.